Contract research organization (CRO) Avetra has officially launched with the aim of introducing a site-centric operating model to realign the relationship between sponsors, CROs, and investigative sites.
With access to more than 350 research-experienced sites and a fully integrated in-house central laboratory, Avetra aims to deliver faster, clearer, and more predictable clinical trial execution.
Avetra provides full-service clinical operations support—including site identification, feasibility, regulatory management, monitoring, and patient-centric execution models—while embedding site-centric workflows into every stage of the study lifecycle. This approach ensures transparent budgeting, stronger communication, and accelerated enrolment, addressing longstanding industry frustrations around inefficiency and misalignment.
Avetra said its model prioritises: real transparency in budgets and timelines; cash-flow-aligned support for investigative sites; faster, more predictable study startup; integrated lab and operational infrastructure; and clear, accountable communication with sponsors.
By combining national site relationships with centralised operational control, Avetra said it can reduce bottlenecks and enable a smoother path from startup to closeout.
Walker Freeman, founder and CEO of Avetra, said: “For decades, investigative sites have shouldered the weight of operational inefficiencies in clinical research. Avetra was built to change that. We believe sponsors deserve transparent execution, sites deserve true partnership, and patients deserve faster access to innovative therapies.
“Our philosophy is simple: empower the sites, respect the financial realities of clinical operations, and execute with the clarity and accountability the industry has been demanding. Avetra isn’t here to compete with the traditional model — we’re here to set a new one.”
Avetra’s network spans research sites in gastroenterology, endocrinology, ophthalmology, obesity, vaccines, and additional therapeutic areas. Its central laboratory division will streamline specimen handling, logistics, and data turnaround.
The company is also preparing to initiate its first large-scale gastrointestinal program in Q3 2026, leveraging its national footprint to execute one of the largest community-based studies in the space.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.